A Huge Decision Is on Tap for This Little Biotech Stock

Investors have their doubts about Geron Corp.'s (NASDAQ: GERN) lead drug candidate, imetelstat, but that didn't keep the company's shares from soaring earlier this year following news that Johnson & Johnson (NYSE: JNJ) will decide whether to continue co-developing imetelstat soon.